For the Quarter Ending September 2025
North America
• In United States, Clobetasol Propionate Price Index rose in Q3 2025, driven by surging API costs and new import tariffs.
• Production costs for Clobetasol Propionate increased due to surging Active Pharmaceutical Ingredient costs in July 2025.
• New US tariffs on pharmaceutical imports, effective August 2025, significantly elevated Clobetasol Propionate input costs.
• Demand for Clobetasol Propionate supported by 5.42% retail sales increase and 4.3% unemployment in September 2025.
• The pharmaceutical supply chain faced Q3 2025 complications from logistical issues, risking Clobetasol Propionate shortages.
• General inflation, at 3.0% CPI in September 2025, contributed to higher operational costs for manufacturers.
• Wholesale electricity prices continued rising across the US in 2025, impacting Clobetasol Propionate manufacturing expenses.
• Pharmaceutical and Biotechnology market sentiment showed an upward trajectory in Q3 2025, with FDA drug approvals surging.
Why did the price of Clobetasol Propionate change in September 2025 in North America?
• Active Pharmaceutical Ingredient costs surged in July 2025, compounded by new US import tariffs from August 2025.
• Logistical issues in the pharmaceutical supply chain constrained availability, risking Clobetasol Propionate shortages in Q3 2025.
• Strong consumer spending, with retail sales up 5.42% and unemployment at 4.3% in September 2025, supported demand.
APAC
• In China, the Clobetasol Propionate Price Index fell quarter-over-quarter in Q3 2025, influenced by declining producer prices and soft domestic demand.
• Clobetasol Propionate production costs trended lower in Q3 2025, with the Producer Price Index falling 2.3% year-on-year in September 2025.
• The demand outlook for Clobetasol Propionate was challenged by a 0.3% year-on-year decline in CPI in September 2025.
• Consumer confidence remained low at 89.6 in September 2025, alongside a 5.2% unemployment rate, impacting healthcare spending.
• The Manufacturing Index was contracting in September 2025, signaling reduced industrial activity affecting Clobetasol Propionate supply.
• Industrial production grew 6.5% year-on-year in September 2025, supporting underlying capacity for pharmaceutical manufacturing.
• Global chemical overcapacity persisted in 2025, contributing to elevated inventories and downward pressure on general chemical input costs.
• Demand for pharmaceutical products was bolstered by an aging population and rising chronic diseases in China during Q3 2025.
Why did the price of Clobetasol Propionate change in September 2025 in APAC?
• Producer Price Index fell 2.3% year-on-year, reducing Clobetasol Propionate production costs.
• Consumer Price Index declined 0.3% year-on-year, indicating soft domestic demand.
• Global chemical overcapacity and contracting Manufacturing Index pressured prices downward.
Europe
• In Germany, the Clobetasol Propionate Price Index remained stable quarter-over-quarter in Q3 2025, balancing various cost and demand factors.
• Clobetasol Propionate production costs were influenced by a -1.7% year-over-year PPI decline, despite a 2.4% CPI in September 2025.
• Demand for Clobetasol Propionate was bolstered by a significant uplift in German pharmaceutical production in July 2025.
• The Clobetasol Propionate demand outlook is supported by an aging population and increasing chronic conditions in Q3 2025.
• Germany's Manufacturing Index was contracting in Q3 2025, signaling a broader industrial sector slowdown.
• Industrial production decreased by 1.0% year-over-year in September 2025, impacting non-API input costs.
• Retail sales increased by 0.2% year-over-year in September 2025, indicating stable consumer purchasing power.
• High electricity prices in Germany during Q3 2025 challenged industrial competitiveness and production expenses.
• The Clobetasol Propionate price forecast suggests continued stability, balancing cost pressures with steady pharmaceutical demand.
Why did the price of Clobetasol Propionate change in September 2025 in Europe?
• Producer prices for intermediate goods declined in Q3 2025, reducing Clobetasol Propionate manufacturing costs.
• German pharmaceutical production increased significantly in July 2025, supporting Clobetasol Propionate supply.
• Stable retail sales, up 0.2% year-over-year in September 2025, maintained consumer affordability for related products.
